We are excited to announce that the paediatric fatty liver disease study using HepaFat-Scan has now commenced in the USA. It is being run in collaboration with the prestigious children’s hospital, Children’s Healthcare of Atlanta. At the date of this release, approximately ten patients have already been recruited and had HepaFat-Scans completed for the study, which commenced last month.
The study will be performed on a paediatric patient population with Non-Alcoholic Fatty Liver Disease (NAFLD). NAFLD is the leading cause of liver disease in the USA and is increasing rapidly worldwide.
In addition to identifying the clinical benefits for the patients involved in this study, the study acts as an independent validation of the HepaFat-Scan technology. The study is therefore important in consolidating the value of HepaFat-Scan in providing an accurate liver fat measurement in NAFLD patients of all ages.
HepaFat-Scan is Resonance Health’s non-invasive medical imaging solution that utilises MRI to accurately measure liver fat. Regulatory clearances have been obtained to market HepaFat-Scan worldwide, with clearances gained in the USA (FDA), EU (CE Mark) and Australia (TGA). The gold standard for assessment of liver fat is currently liver biopsy which is painful, invasive and lacking in sensitivity due to its subjective and semi-quantitative nature.
HepaFat-Scan may assist clinicians in their diagnosis and treatment of patients, providing them with accurate information at an earlier disease stage. This study intends to demonstrate that this information may lead to improved patient outcomes. Collecting such data may ultimately support the inclusion of HepaFat-Scan in clinical guidelines for routine care of NAFLD patients.
There are currently no approved pharmaceutical treatments for NAFLD and as such HepaFat-Scan is very well suited to be utilised by pharmaceutical companies who are currently racing to develop treatments for NAFLD and associated diseases.